Personal Investment Vitae

Home > Personal Investment Vitae

AYA Personal Investment Vitae as of February 2026
Olivia London @Olivia London
Platinum member since January 2017

Location: United States

Gender: Female

Asset investment style: Hybrid analysis

Market capitalization:

$7,968,367talents

Virtual portfolio value:

$5,026,555talents

Net overall return per annum:

19.34%

AYA current rank order:

#14

Asset investment philosophy:
Olivia London trades U.S. stocks with the top #176 to #500 positive alpha signals.

Top 10 profitable stock transactions since January 2020Strategy

Symbol Company Buy Sell Share Volume Return (%) Profit ($)
RMBL RumbleOn Inc. Class B Common Stock $0.36 $7.95 21,280 +2,108.33% $161,515
VATE INNOVATE Corp. Common Stock $0.53 $4.14 44,545 +681.13% $160,807
BQ Boqii Holding Limited American Depositary Shares representing Class A Ordinary Shares $0.36 $3.36 47,977 +833.33% $143,931
BQ Boqii Holding Limited Class A Ordinary Shares $0.36 $3.36 47,977 +833.33% $143,931
XBIOW Xenetic Biosciences Inc. Warrants $2.00 $23.16 5,273 +1,058.00% $111,577
LGVN Longeveron Inc. Class A Common Stock $3.45 $26.25 3,044 +660.87% $69,403
LSCC Lattice Semiconductor Corporation Common Stock $6.97 $48.04 1,078 +589.24% $44,273
FIVN Five9 Inc. Common Stock $16.31 $110.10 460 +575.05% $43,143
GLOB Globant S.A. Common Shares $34.57 $215.99 217 +524.79% $39,368
HZNP Horizon Therapeutics Public Limited Company Ordinary Shares $16.41 $98.56 458 +500.61% $37,625
Sum $955,573

Top 10 current stock portfolio positions as of February 2026Strategy

Top 20 influencers

#1 - #5 #6 - #10 #11 - #15 #15 - #20
@Andy Yeh Alpha

Blog+More

MIT financial economist Simon Johnson rethinks capitalism with better key market incentives.

Daisy Harvey

2019-11-23 08:33:00 Saturday ET

MIT financial economist Simon Johnson rethinks capitalism with better key market incentives.

MIT financial economist Simon Johnson rethinks capitalism with better key market incentives. Johnson refers to the recent Business Roundtable CEO statement

+See More

Apple releases its September 2018 trifecta of smart phones or iPhone X sequels: iPhone Xs, iPhone Xs Max, and iPhone XR.

Jacob Miramar

2018-09-15 11:35:00 Saturday ET

Apple releases its September 2018 trifecta of smart phones or iPhone X sequels: iPhone Xs, iPhone Xs Max, and iPhone XR.

Apple releases its September 2018 trifecta of smart phones or iPhone X sequels: iPhone Xs, iPhone Xs Max, and iPhone XR. Both iPhone Xs and iPhone Xs Max ha

+See More

Pinterest files a $12 billion IPO due in mid-2019.

Laura Hermes

2019-03-09 12:43:00 Saturday ET

Pinterest files a $12 billion IPO due in mid-2019.

Pinterest files a $12 billion IPO due in mid-2019. This tech unicorn allows users to pin-and-browse images through its social media app and website. Pintere

+See More

Hong Kong billionaire Li Ka-Shing announces his retirement in March 2018 with an incredible rags-to-riches life story.

John Fourier

2018-03-11 08:27:00 Sunday ET

Hong Kong billionaire Li Ka-Shing announces his retirement in March 2018 with an incredible rags-to-riches life story.

At 89 years old, Hong Kong billionaire Li Ka-Shing announces his retirement in March 2018. With a personal net worth of $35 billion, Li has an incredible ra

+See More

In the current global market for better biotech advances, medical innovations, and healthcare services, the new integration of artificial intelligence (AI) reshapes the competitive landscape worldwide.

Charlene Vos

2026-04-30 08:28:00 Thursday ET

In the current global market for better biotech advances, medical innovations, and healthcare services, the new integration of artificial intelligence (AI) reshapes the competitive landscape worldwide.

In the current global market for better biotech advances, medical innovations, and healthcare services, the new integration of artificial intelligence (AI)

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More